Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination pharmaceutical therapies for obesity.

Literature DB >> 19351275

Combination pharmaceutical therapies for obesity.

Abstract

The anti-obesity medications available at present achieve a rather modest degree of weight loss that falls below the expectations of clinicians as well as consumers. Several combination drug therapies are in development with the aim of achieving better results that would be clinically more meaningful in the reduction of obesity-related health risks. This paper discusses the pros and cons of combination therapies, and the ongoing research in this area.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Anti-Obesity Agents

Year: 2009 PMID： 19351275 PMCID： PMC4780673 DOI： 10.1517/14656560902824152

Source DB: PubMed Journal: Expert Opin Pharmacother ISSN： 1465-6566 Impact factor: 3.889

22 in total

1. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.

Authors: Kishore M Gadde; David B Allison
Journal: Circulation Date: 2006-08-29 Impact factor: 29.690

Review 2. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice.

Authors: J D Douketis; C Macie; L Thabane; D F Williamson
Journal: Int J Obes (Lond) Date: 2005-10 Impact factor: 5.095

3. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.

Authors: M Weintraub; P R Sundaresan; M Madan; B Schuster; A Balder; L Lasagna; C Cox
Journal: Clin Pharmacol Ther Date: 1992-05 Impact factor: 6.875

Review 4. Bupropion for weight reduction.

Authors: Kishore M Gadde; Glen L Xiong
Journal: Expert Rev Neurother Date: 2007-01 Impact factor: 4.618

5. Rational design of a combination medication for the treatment of obesity.

Authors: Frank L Greenway; M J Whitehouse; Maria Guttadauria; James W Anderson; Richard L Atkinson; Ken Fujioka; Kishore M Gadde; Alok K Gupta; Patrick O'Neil; Donald Schumacher; Diane Smith; Eduardo Dunayevich; Gary D Tollefson; Eckard Weber; Michael A Cowley
Journal: Obesity (Silver Spring) Date: 2008-11-06 Impact factor: 5.002

6. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.

Authors: M Weintraub; J D Hasday; A I Mushlin; D H Lockwood
Journal: Arch Intern Med Date: 1984-06

Review 7. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

Authors: Robin Christensen; Pernelle Kruse Kristensen; Else Marie Bartels; Henning Bliddal; Arne Astrup
Journal: Lancet Date: 2007-11-17 Impact factor: 79.321

8. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial.

Authors: A Astrup; L Breum; S Toubro; P Hein; F Quaade
Journal: Int J Obes Relat Metab Disord Date: 1992-04

9. Long-term persistence with orlistat and sibutramine in a population-based cohort.

Authors: R Padwal; A Kezouh; M Levine; M Etminan
Journal: Int J Obes (Lond) Date: 2007-04-10 Impact factor: 5.095

10. Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study.

Authors: Jesper Hallas; Lars Bjerrum; Henrik Støvring; Morten Andersen
Journal: Am J Epidemiol Date: 2008-08-27 Impact factor: 4.897

8 in total

Combination pharmaceutical therapies for obesity.

1. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.

Review 2. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice.

3. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.

Review 4. Bupropion for weight reduction.

5. Rational design of a combination medication for the treatment of obesity.

6. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.

Review 7. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

8. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial.

9. Long-term persistence with orlistat and sibutramine in a population-based cohort.

10. Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study.

1. On the behavioural specificity of hypophagia induced in male rats by mCPP, naltrexone, and their combination.

Review 2. Obesity: Current and potential pharmacotherapeutics and targets.

3. The clinical pharmacology of obesity.

Review 4. Long-term drug treatment for obesity: a systematic and clinical review.

5. Pharmacotherapies for obesity: past, current, and future therapies.

Review 6. The limits and challenges of antiobesity pharmacotherapy.

7. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity.

Review 8. Combinations of drugs in the Treatment of Obesity.